Advertisement
ABVX vs RVMD
Abivax (ABVX) vs Revolution Medicines (RVMD) Earnings Recap: Full-Year 2025 Financial Results and Pipeline Momentum
Key Takeaways
- Abivax reported a full-year 2025 net loss of €336.1 million on operating income of €4.6 million, with R&D expenses rising 21% to €177.8 million driven by obefazimod development.
- Revolution Medicines posted a Q4 2025 EPS of ($1.86), full-year ($5.95), amid ramped-up R&D for RAS(ON) inhibitors; 2026 operating expenses guided to $1.6-$1.7 billion.
- Abivax ended 2025 with €530.4 million in cash, runway into Q4 2027; Revolution Medicines held $2.0 billion, supporting multiple Phase 3 trials.
- Both biotechs focus on high-unmet-need areas: Abivax in inflammatory bowel disease via obefazimod Phase 3, Revolution Medicines in RAS-addicted oncology.
- Market speculation positions both as attractive M&A targets, with Abivax leading surveys for IBD potential and RVMD for oncology precision therapies.
- Investor focus shifts to Abivax's ABTECT-UC topline in late Q2 2026 and RVMD's RASolute 302 readout in H1 2026.
Earnings Context and Why This Comparison Matters
Abivax SA (ABVX) and Revolution Medicines, Inc. (RVMD) represent cutting-edge biotechs tackling immune-mediated and oncology challenges. Abivax develops obefazimod to modulate immune responses in ulcerative colitis and Crohn's disease, while Revolution Medicines pioneers RAS(ON) inhibitors for hard-to-treat cancers like pancreatic ductal adenocarcinoma. Their full-year 2025 results highlight escalating R&D investments amid no commercial revenue, underscoring cash burn in late-stage development. This comparison matters as both navigate pivotal trials, with strong cash positions funding readouts that could validate platforms and draw big pharma interest in immunology and precision oncology.
Abivax Focus
Abivax released full-year 2025 financial results on March 23, 2026, covering the fiscal year ended December 31, 2025. Operating income fell to €4.6 million from €12.4 million in 2024, reflecting grant and collaboration reductions. Operating expenses climbed to €250.7 million, yielding an operating loss of €246.1 million, up from €173.0 million. R&D expenses, 70.9% of total, surged 21.3% to €177.8 million—96.5% tied to obefazimod—driven by CMC/supply chain, Crohn's trials, and new indications. G&A rose to €67.7 million on personnel and AGA plans. Net loss widened to €336.1 million, impacted by non-cash items like €35.4 million share-based compensation. Cash reached €530.4 million post-July 2025 offering, funding operations into Q4 2027. Pipeline advances include Phase 3 ABTECT-UC maintenance (DSMB positive March 18, 2026) and Crohn's expansion.
Revolution Medicines Context
Revolution Medicines reported Q4/full-year 2025 results on February 25, 2026. Q4 EPS was ($1.86) versus consensus ($1.56), with net loss of $364.9 million. Full-year EPS reached ($5.95), reflecting heavy R&D ramp-up absent revenue. Q4 R&D expenses hit $294.9 million, up from $188.1 million prior year, fueling daraxonrasib (RMC-6236), zoldonrasib, and others. Cash stood at $2.0 billion end-2025, bolstered by Royalty Pharma tranche; $1.75 billion committed remains. 2026 guidance flags $1.6-$1.7 billion operating expenses, including $180-$200 million stock-based pay. Fundamentals emphasize pipeline: RASolute 302 (PDAC) readout H1 2026, RASolve 301 (NSCLC) enrollment near-complete, new Phase 3s in G12D PDAC and doublets.
Head-to-Head Earnings and Market Comparison
Both firms reported deepening losses—Abivax's €336.1 million net loss (~$365 million) versus RVMD's ~$1.1 billion—tied to R&D escalation without revenue. Abivax's burn (~€161 million operating cash) is more contained than RVMD's aggressive $1.6 billion 2026 spend, but RVMD's $2 billion cash dwarfs Abivax's €530 million, offering superior endurance. Growth drivers diverge: Abivax banks on obefazimod's Phase 3 efficacy in IBD (topline Q2 2026), potentially disruptive orally; RVMD's RAS(ON) multi-asset engine targets vast oncology market, with daraxonrasib OS data critical. Risks include trial failures—Abivax UC maintenance, RVMD PDAC survival—and dilution. Sentiment favors RVMD's broader pipeline and M&A buzz (AbbVie talks), though Abivax leads IBD buyout polls; both trade on catalysts amid biotech volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform’s top-performing AI trading bots under live market conditions. With hundreds of bots scanning thousands of tickers across strategies like momentum, mean reversion, and scalping—spanning minutes to months—the curated section highlights only those with the strongest risk-adjusted returns, win rates often exceeding 60%, and drawdown controls. Performance metrics reveal top bots delivering 20-50% annualized returns in backtests and live trading, adapting dynamically to volatility in sectors like biotech. This neutral selection aids traders in identifying bots suited to ABVX or RVMD trends. Explore the page to deploy or monitor these leaders today.
Tickeron AI Verdict
Tickeron AI leans toward RVMD (~65% probability) for superior cash reserves, diversified oncology pipeline, and Phase 3 catalysts, despite higher burn. Abivax offers IBD upside but narrower focus and forex risks temper stability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVX is a Hold and RVMD is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABVX’s FA Score shows that 0 FA rating(s) are green whileRVMD’s FA Score has 1 green FA rating(s).
- ABVX’s FA Score: 0 green, 5 red.
- RVMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABVX’s TA Score shows that 7 TA indicator(s) are bullish while RVMD’s TA Score has 5 bullish TA indicator(s).
- ABVX’s TA Score: 7 bullish, 3 bearish.
- RVMD’s TA Score: 5 bullish, 5 bearish.
Price Growth
ABVX (@Biotechnology) experienced а -4.74% price change this week, while RVMD (@Biotechnology) price change was +54.12% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
ABVX is expected to report earnings on May 25, 2026.
RVMD is expected to report earnings on May 11, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABVX | RVMD | ABVX / RVMD | |
| Capitalization | 9.66B | 31B | 31% |
| EBITDA | -170.04M | -1.09B | 16% |
| Gain YTD | -10.897 | 86.591 | -13% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 0 | 0 | - |
| Total Cash | 104M | 2.03B | 5% |
| Total Debt | 92.6M | 159M | 58% |
RVMD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 14 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 35 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ABVX | RVMD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 73% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 80% |
| Advances ODDS (%) | 9 days ago 88% | 4 days ago 80% |
| Declines ODDS (%) | 20 days ago 81% | 2 days ago 72% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 83% |
Advertisement